Cargando…

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma

Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuli, Guo, Zhitao, Li, Yang, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/
https://www.ncbi.nlm.nih.gov/pubmed/28352770
http://dx.doi.org/10.1515/med-2016-0014
_version_ 1782511128692129792
author Wang, Yuli
Guo, Zhitao
Li, Yang
Zhou, Qinghua
author_facet Wang, Yuli
Guo, Zhitao
Li, Yang
Zhou, Qinghua
author_sort Wang, Yuli
collection PubMed
description Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for 50%–60% of resistant tumors. A large amount of studies have focused on the development of effective strategies to treat TKI-resistant EGFR T790M mutation in lung tumors. Novel generations of EGFR inhibitors are producing encouraging results in patients with acquired resistance against EGFR T790M mutation. This review will summarize the novel inhibitors, which might overcome resistance against EGFR T790M mutation.
format Online
Article
Text
id pubmed-5329801
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher De Gruyter Open
record_format MEDLINE/PubMed
spelling pubmed-53298012017-03-28 Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma Wang, Yuli Guo, Zhitao Li, Yang Zhou, Qinghua Open Med (Wars) Review Article Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for 50%–60% of resistant tumors. A large amount of studies have focused on the development of effective strategies to treat TKI-resistant EGFR T790M mutation in lung tumors. Novel generations of EGFR inhibitors are producing encouraging results in patients with acquired resistance against EGFR T790M mutation. This review will summarize the novel inhibitors, which might overcome resistance against EGFR T790M mutation. De Gruyter Open 2016-03-26 /pmc/articles/PMC5329801/ /pubmed/28352770 http://dx.doi.org/10.1515/med-2016-0014 Text en © 2016 Yuli Wang et al http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Review Article
Wang, Yuli
Guo, Zhitao
Li, Yang
Zhou, Qinghua
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title_full Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title_fullStr Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title_full_unstemmed Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title_short Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
title_sort development of epidermal growth factor receptor tyrosine kinase inhibitors against egfr t790m. mutation in non small-cell lung carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/
https://www.ncbi.nlm.nih.gov/pubmed/28352770
http://dx.doi.org/10.1515/med-2016-0014
work_keys_str_mv AT wangyuli developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma
AT guozhitao developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma
AT liyang developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma
AT zhouqinghua developmentofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsagainstegfrt790mmutationinnonsmallcelllungcarcinoma